Aviance Capital Partners LLC Raises Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Aviance Capital Partners LLC increased its position in Edwards Lifesciences Co. (NYSE:EW) by 8.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 7,794 shares of the medical research company’s stock after purchasing an additional 600 shares during the period. Aviance Capital Partners LLC’s holdings in Edwards Lifesciences were worth $577,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Concurrent Investment Advisors LLC increased its position in Edwards Lifesciences by 3.4% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 19,187 shares of the medical research company’s stock valued at $1,266,000 after purchasing an additional 636 shares during the period. Kornitzer Capital Management Inc. KS increased its position in Edwards Lifesciences by 30.6% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 119,535 shares of the medical research company’s stock valued at $7,888,000 after purchasing an additional 27,985 shares during the period. Sittner & Nelson LLC increased its position in Edwards Lifesciences by 3.0% during the 3rd quarter. Sittner & Nelson LLC now owns 24,745 shares of the medical research company’s stock valued at $1,633,000 after purchasing an additional 730 shares during the period. Presidio Capital Management LLC purchased a new position in Edwards Lifesciences during the 3rd quarter valued at $527,000. Finally, AIA Group Ltd increased its position in Edwards Lifesciences by 91.7% during the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock valued at $49,461,000 after purchasing an additional 358,556 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

EW has been the topic of a number of research analyst reports. The Goldman Sachs Group boosted their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their target price for the company from $82.00 to $90.00 in a report on Monday, December 16th. Piper Sandler boosted their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Truist Financial restated a “hold” rating and set a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $79.95.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 6,500 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,555,402. This represents a 12.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,739 shares of company stock valued at $2,799,104. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $70.36 on Friday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The business has a 50-day simple moving average of $72.26 and a two-hundred day simple moving average of $70.38. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market cap of $41.50 billion, a price-to-earnings ratio of 10.10, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.